Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors.

Autor: Clemente V; Masonic Cancer Center and Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA., Hoshino A; Masonic Cancer Center and Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA., Shetty M; Masonic Cancer Center and Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA., Nelson A; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA., Erickson BK; Masonic Cancer Center and Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA., Baker R; Masonic Cancer Center and Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA., Rubin N; Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA., Khalifa M; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA., Weroha SJ; Departments of Oncology and Molecular Pharmacology, Mayo Clinic, Rochester, MN, USA., Lou E; Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA., Bazzaro M; Masonic Cancer Center and Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA.

Publikováno v: Cancer research communications [Cancer Res Commun] 2022 Aug; Vol. 2 (8), pp. 784-794. Date of Electronic Publication: 2022 Aug 10.